Online inquiry

IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1553MR)

This product GTTS-WQ1553MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets BMP10&GDF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014482.3; NM_016204.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27302; 2658
UniProt ID O95393; Q9UK05
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1553MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13663MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ7520MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ14548MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ10918MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ7270MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ7059MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ4198MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ4261MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW